How to Place a Medical Device on the Canadian Market in 2026: Medical Device Licence versus Medical Device Establishment Licence versus Class I, MDSAP as a Licence Condition not a Substitute, Official Fees as of 1 April 2026, and Why SOR/2026-110's Coming-into-Force Date Is Counted from Registration not from the MDCP Bulletin

Does a CE mark, 510(k), NMPA certificate or MDSAP certificate replace a Canadian Medical Device Licence?

A widespread and costly misconception among international medical-device exporters is that holding an active European Union CE certificate under MDR 2017/745, a United States FDA 510(k) premarket clearance, or a National Medical Products Administration (NMPA) registration certificate from China confers automatic market access in Canada. It does not. The Canadian regulatory framework operates under sovereign statutory rules enacted in the Food and Drugs Act and administered by Health Canada through the Medical Devices Regulations (SOR/98-282) ¹.

The cornerstone of Canadian medical device law is Section 26 of SOR/98-282, which establishes an unequivocal statutory prohibition: “Subject to section 37, no person shall import or sell a Class II, III or IV medical device unless the manufacturer of the device holds a licence in respect of that device or, if the medical device has been subjected to a change described in section 34, an amended medical device licence.” ¹ In Canadian law, the Medical Device Licence (MDL) is a product-specific pre-market authorization issued directly to the legal manufacturer named on the label. No overseas registration, regardless of the issuing authority's stature, bypasses this statutory mandate.

Overseas regulatory approvals serve exclusively as supporting evidentiary assets within a Canadian submission dossier, not as statutory substitutes. For example, clinical investigation data generated for a European CE dossier or biocompatibility testing conducted in accordance with ISO 10993 for an FDA 510(k) submission can be integrated into a Class III or Class IV Canadian licence application. However, Health Canada's Medical Devices Bureau conducts an independent assessment of safety, effectiveness, and risk classification under Canadian rules before granting an MDL. A CE Declaration of Conformity or FDA clearance letter does not satisfy s 26. Treat those documents as supporting evidence in a Canadian file after you have verified the CE certificate or verified the 510(k) number, and after you have verified any China NMPA certificate used as country-of-origin evidence. If a Certificate of Free Sale is requested for a Canada-bound file, verify the issuing authority rather than treating it as an MDL ¹.

Who files the MDL, and why Canada does not use an Australian-sponsor or Saudi-AR model

When planning market entry into Canada, commercial teams familiar with other major medical device jurisdictions frequently look for an in-country authorized representative or “sponsor” to hold their product registration. For example, placing a device in Australia requires an Australian-resident or incorporated Australian Sponsor under Section 3 of the Therapeutic Goods Act 1989, as detailed in our guide to Australian TGA ARTG inclusion and sponsor requirements. Similarly, entering the Kingdom of Saudi Arabia mandates an in-country Authorized Representative holding an SFDA-issued AR licence, as examined in our analysis of Saudi SFDA MDMA market placement, and Great Britain requires a UK Responsible Person (UKRP) under UK MHRA market placement rules.

Canada does not follow this in-country representative model for product licensing. Under Section 32 of SOR/98-282, the applicant and ultimate holder of a Medical Device Licence must be the legal manufacturer—defined under Section 1 as the person who sells the medical device under their own name, or under a trademark, design, trade name or other name or mark owned or controlled by the person, and who is responsible for designing, manufacturing, assembling, processing, labelling, packaging, refurbishing or modifying the device, or for assigning to it a purpose, whether those tasks are performed by that person or on their behalf ¹.

An overseas manufacturer based in China, Germany, the United States, or elsewhere files directly with Health Canada. There is no statutory requirement or mechanism to appoint a Canadian “licence holder” or intermediary representative to own the MDL. The application is submitted electronically through Health Canada's Regulatory Enrolment Process (REP) using the Common Electronic Submission Gateway (CESG) ¹⁰. While an overseas manufacturer may designate an external regulatory consultant or agent to act as the administrative contact during dossier review, the resulting Medical Device Licence is issued exclusively in the legal name and corporate address of the manufacturer that appears on the device packaging and labelling ^{1 10}.

When a Class II–IV manufacturer needs MDEL — and when GUI-0016 Table 1 says they do not

While the Medical Device Licence (MDL) governs the product, the Medical Device Establishment Licence (MDEL) governs physical and commercial distribution activities within the supply chain under Section 44 of SOR/98-282 ¹. Misunderstanding the intersection between these two licence types is one of the most common operational errors in Canadian market planning.

In recent months, automated search summaries and AI-generated overviews (including Google's MDEL-versus-MDL AI Overview) have widely disseminated inaccurate regulatory guidance, asserting that any manufacturer of Class II, III, or IV devices who exports directly into Canada must obtain both an MDL and an MDEL. This assertion contradicts Health Canada's establishment-licensing guidance. GUI-0016 is administrative guidance: the Act and the Regulations take precedence on conflict. Table 1 is titled MDEL requirement based on activity type ⁴:

I am in or outside Canada. I only sell Class II, III or IV medical devices in Canada that have my name on the label as the manufacturer. I do not sell Class I medical devices in Canada. — No MDEL (An MDL is required).— Health Canada, GUI-0016 Table 1, manufacturing row (issued 26 July 2024, effective 14 December 2024)

Under GUI-0016 and Section 44(2) of the Regulations, a manufacturer of licensed Class II–IV devices who ships directly to a Canadian commercial importer or hospital is exempt from holding an MDEL, provided the devices carry the manufacturer's own name on the label and the manufacturer does not distribute other companies' medical devices or Class I products ^{4 5}. Instead, the burden of establishment licensing falls squarely on the Canadian Importer. The Canadian entity that takes physical receipt of the shipment and clears customs must hold an active MDEL with authorized importation activities for the appropriate device risk classes ⁴.

How Class I is authorised without an MDL, and why those devices never appear in MDALL

In Canada's risk-based framework (Schedule 1 of SOR/98-282), medical devices are classified into four classes: Class I represents the lowest risk potential (e.g., non-invasive manual surgical instruments, basic bandages, examination lights, catheter securement straps), progressing to Class IV for high-risk implantable cardiovascular and life-supporting devices ^{1 15}.

A fundamental structural feature of the Canadian system is that Class I medical devices are entirely exempt from pre-market Medical Device Licensing. Health Canada does not issue an MDL for a Class I device, does not review a Class I pre-market technical dossier, and does not list Class I devices on MDALL ². Prospective buyers who search MDALL for a Class I consumable and conclude that the device is “unregistered” or “unlicensed” are applying the wrong regulatory test.

Market oversight for Class I devices is exercised entirely through the establishment licensing regime (MDEL). Under Section 44 of SOR/98-282, anyone who manufactures a Class I device in Canada, or who imports or distributes a Class I device in Canada, must hold an active MDEL ^{1 4}. During the MDEL application process (using Form FRM-0292), the applicant does not register individual device trade names; rather, they attest under senior management authority that they have established and maintain documented standard operating procedures (SOPs) for distribution record-keeping, complaint handling, recall execution, mandatory problem reporting, and storage/handling conditions ^{4 5}.

For an overseas manufacturer of Class I devices, market entry is straightforward: as long as the devices are sold in Canada exclusively through a Canadian importer that holds an active MDEL, the overseas manufacturer does not need an MDL, does not need an MDEL, and does not need to submit an MDSAP audit certificate ^{4 5}. The legal compliance gate resides with the Canadian importer's establishment licence and the manufacturer's technical file confirming Class I qualification under Schedule 1 rules ^{1 15}.

What MDSAP actually is in a Canadian file: an MDL condition, not the licence

Since 1 January 2019, Health Canada has mandated participation in the Medical Device Single Audit Program (MDSAP) for all manufacturers applying for or maintaining Class II, III, and IV Medical Device Licences, fully replacing the former Canadian Medical Devices Conformity Assessment System (CMDCAS) ^{1 10}. However, regulatory and commercial teams frequently confuse the role of MDSAP within a Canadian filing.

MDSAP is not a marketing authorization, and an MDSAP certificate is not a Medical Device Licence. Rather, holding an active MDSAP certificate issued by a Health Canada-recognized Auditing Organisation (AO)—such as BSI, TÜV SÜD, DEKRA, SGS, or DNV—is a mandatory statutory pre-condition under Section 32(2)(f), 32(3)(j), and 32(4)(p) of SOR/98-282 ¹. When filing a new MDL application via REP, the manufacturer must upload a legible copy of their valid MDSAP certificate, identify the auditing organisation, and state the exact certificate number and facility scope ¹⁰.

Crucially, a standard ISO 13485:2016 certificate issued outside the MDSAP framework—even if issued by a prestigious European notified body for CE marking purposes—is legally invalid for a Canadian Class II, III, or IV MDL application ¹⁰. For a detailed breakdown of how to audit and verify quality management system certificates and confirm MDSAP scope statements, consult our comprehensive guide on how to verify ISO 13485 and MDSAP certificates. If a foreign supplier provides an ISO 13485 certificate without the official MDSAP companion statement and recognized AO identifier, their Canadian MDL application cannot pass Health Canada's screening stage ¹⁰.

What the official 1 April 2026 fee cards print for MDL, private-label MDL, right-to-sell and MDEL

Health Canada adjusts its regulatory fees annually on 1 April under the Fees in Respect of Drugs and Medical Devices Order based on the Consumer Price Index (CPI). Operating with outdated consultancy fee estimates or generic USD estimates leads to immediate financial and operational friction. Below are the official statutory fees effective from 1 April 2026 to 31 March 2027 and the Review 1 clocks printed in the Performance Standards Order ^{6 7 8 18}.

As illustrated above, Health Canada's fee structure heavily penalises higher-risk device submissions, with Class III applications set at CAD 14,163 and Class IV at CAD 30,713, reflecting the intensive multi-disciplinary scientific review required for implantable and cardiovascular technologies ⁶. In contrast, a Class II application — the planning class for many sterile single-use surgical consumables, subject to the manufacturer's Schedule 1 determination — prints an initial fee of CAD 643, with licence amendments priced at CAD 331 ⁶.

Two operational rules governing Health Canada timelines require rigorous management by importers and manufacturers ^{5 14}:

• MDEL 120-Day Performance Standard & 25% Fee Credit: Health Canada commits to issuing a regulatory decision on an MDEL application within 120 calendar days of receiving a complete, paid application. Under the Service Fees Act and Health Canada fee policies, if Health Canada misses this 120-day performance standard, the applicant is entitled to a mandatory 25% fee remission (credit) ¹⁴.
• Cost-Recovery Holds & Pause-the-Clock: When Health Canada issues a fee invoice, payment is due within 30 calendar days. If an invoice remains unpaid past day 30, the application is placed on immediate cost-recovery hold, and the 120-day review clock pauses until funds clear. Similarly, for Class III and IV applications, issuing a formal Request for Additional Information (screening or review deficiency notice) pauses the review clock ^{10 14}.

What a private-label MDL is, what it costs, and why the original manufacturer's licence and letter still come first

For international medical device distributors, hospital buying groups, and OEM brand owners seeking to commercialise Chinese or European manufactured devices under their own proprietary brand name in Canada, the Private Label Medical Device Licence represents one of the most efficient commercial pathways in global medical device regulation ⁹.

Under Health Canada's Guidance Document — Private Label Medical Devices, a private-label medical device is defined as a device that is “identical in every respect to a medical device manufactured by an original manufacturer and licensed by Health Canada, except that the device is labelled with the private label manufacturer's name, address and product name and identifier.” ⁹

The financial and procedural benefits of the private-label pathway are substantial ^{6 9}:

• Reduced Statutory Application Fee: As of 1 April 2026, the application fee for a private-label MDL across Class II, Class III, or Class IV is fixed at CAD 179 ⁶. This represents an enormous cost reduction compared to an original Class III filing (CAD 14,163) or Class IV filing (CAD 30,713).
• Abridged Review Timeframe: Because safety, clinical performance, and manufacturing processes have already been established in the original manufacturer's master file, Health Canada's Performance Standards Order prints a 15-calendar-day Review 1 target for private-label applications — the same screening-period target as a Class II file, not a scientific Class III/IV review ¹⁸.
• Legal Status as Manufacturer: Under Canadian law, the private-label brand owner is legally designated as the “manufacturer” for that private-label licence. However, because manufacturing is performed on their behalf, Health Canada does not require the private-label owner to submit their own MDSAP certificate, relying instead on the original manufacturer's MDSAP compliance ⁹.

However, two strict legal prerequisites must be satisfied before a private-label MDL can be granted ⁹:

• Original Manufacturer MDL Must Pre-Exist: A private-label application cannot be filed concurrently with an original manufacturer application. The original equipment manufacturer (OEM) must already hold an issued, active Medical Device Licence on MDALL for that exact product model ^{2 9}.
• Mandatory Letter of Authorisation (LoA): The original manufacturer must execute a formal, signed Letter of Authorisation (following Health Canada's prescribed template) granting Health Canada permission to cross-reference their proprietary technical file, design dossiers, and MDSAP certificate on behalf of the private-label applicant ⁹.

For brand owners structuring OEM supply agreements, establishing clear contractual obligations regarding who owns and maintains the original MDL, who pays the annual right-to-sell fees, and how design modifications or Section 34 licence amendments are coordinated is essential. For further guidance on structuring OEM and private-label contracts, see our medical device contract manufacturing buyer guide.

What MDALL can and cannot prove, versus what the MDEL listing can and cannot prove

Health Canada maintains two distinct, publicly accessible online databases to monitor compliance: the Medical Devices Active Licence Listing (MDALL) and the Medical Devices Establishment Licence (MDEL) Listing. International buyers, procurement auditors, and distributors frequently confuse what each database verifies ^{2 3 16}.

Our independent analysis of the Health Canada MDALL database snapshot dated 6 July 2026 (source: Health Canada MDALL API and Open Government extract) recomputes exactly 35,387 active licence records representing 153,142 individual device rows across 3,375 active licence-holding corporations ¹⁶. As demonstrated in the chart above, Class II represents the vast majority of licensed medical technology in Canada (26,077 licences; 73.7%), followed by Class III (7,748 licences; 21.9%), and Class IV (1,562 licences; 4.4%) ¹⁶.

Geographic analysis of active licence holders reveals that international manufacturers dominate Canadian medical device supply: the United States accounts for 1,241 active licence-holding companies, Canada represents 533, and China represents 366 active licence holders (with 2,128 licensed product families attributed) ¹⁶. However, when querying MDALL and the MDEL directory during supplier due diligence, procurement teams must enforce four strict verification boundaries ^{2 3 16}:

• MDALL Contains Zero Class I Devices: Because Class I devices do not require an MDL, there are zero Class I entries in MDALL. A query returning zero results for a manual scalpel, disposable skin marker, or wound dressing does not indicate non-compliance ^{2 16}.
• MDEL Listing Contains No Product Names: The MDEL database lists establishment identity, physical locations, licensed activities (import/distribute/manufacture), and authorized risk classes. Health Canada explicitly states on the listing: “Health Canada does not maintain a list of products under an MDEL. The MDEL does not constitute approval of any specific medical device.” An MDEL screenshot proves only that an importer is licensed to operate, not that a specific product is authorized ³.
• A Public MDALL Row Is Not Your Licence: Each MDL is legally unique to the specific manufacturer named on the application. Searching MDALL and finding another company's active licence for an identical device model (e.g., another brand's circumcision tray or laser fiber) confers zero legal authorization for you to import that model under your supply chain ^{1 2}.
• Corporate Entity Disambiguation: A search for “Medison” on MDALL returns active licences held by Samsung Medison Co., Ltd. (a South Korean ultrasound manufacturer) and historic records for Medison America Inc., which are entirely distinct corporate entities from Weihai Medison Medical Equipment Co., Ltd. Regulatory verification requires matching the exact company identifier, legal name, and physical manufacturing address against the packaging label ¹⁶.

What SOR/2026-110 changes for foreign distributors, supplier lists and documented procedures — and which coming-into-force date the instrument actually prints

On 4 June 2026, the Governor General in Council registered significant statutory amendments to the Medical Devices Regulations entitled Regulations Amending the Medical Devices Regulations (Establishment Licences), officially designated as SOR/2026-110 and published in the Canada Gazette, Part II on 17 June 2026 ¹¹. This regulatory modernization—often referred to as Phase 2 of Health Canada's establishment licensing initiative—restructures international distributor obligations and supply chain tracking ^{11 12}.

SOR/2026-110 enacts three transformative regulatory changes ¹¹:

• Section 44(4) Foreign Distributor Exemption: Under current GUI-0016 guidance (effective 14 December 2024), any entity outside Canada that acts as a non-manufacturer distributor and sells medical devices into Canada is technically required to hold an MDEL. SOR/2026-110 replaces subsection 44(4). After coming into force, a Canadian establishment-licence holder who imports a device from someone other than the manufacturer is no longer required under s 44(3) to ensure that foreign seller holds an MDEL. The Regulatory Impact Analysis Statement states the corresponding policy: foreign distributors selling through a licensed Canadian MDEL holder will no longer be required to hold their own MDEL ^{4 11}.
• Mandatory Supplier Roster (Section 45(f.1) & (f.2)): To counterbalance the foreign distributor exemption and ensure supply chain traceability, SOR/2026-110 amends Section 45 to require every MDEL applicant and holder to submit and maintain the name and address of each person (other than the manufacturer) who sells a medical device to them for importation or distribution, along with the risk classes of those devices ¹¹.
• Explicit Documented Procedures Mandate: The amendments explicitly codify statutory obligations for MDEL holders to maintain documented procedures for distribution record-keeping, complaint handling, recalls, mandatory problem reporting, and environmental storage controls ^{11 13}.

A critical, unresolved discrepancy exists regarding the exact legal coming-into-force date of SOR/2026-110. Section 10 of the statutory instrument published in Canada Gazette Part II explicitly provides: “These Regulations come into force on the 180th day after the day on which they are registered.” ¹¹ The official registration date on the instrument is 4 June 2026. Calculating 180 calendar days from 4 June 2026 yields a strict statutory coming-into-force date of 1 December 2026 ¹¹.

Conversely, Health Canada's Medical Devices Compliance Program (MDCP) Bulletin issued on 17 June 2026 and the draft GUI-0016 guidance header state that the amendments will come into force on 14 December 2026, having calculated 180 days from the Gazette publication date (17 June 2026) rather than the registration date ^{12 13}. Furthermore, the Regulatory Impact Analysis Statement (RIAS) references “six months from the date of registration,” which corresponds to 4 December 2026 ¹¹.

Prudent distributors and regulatory managers should plan compliance against the earliest statutory date—1 December 2026. Until SOR/2026-110 takes effect, the 14 December 2024 edition of GUI-0016 remains in force, and foreign distributors selling directly into Canada must maintain their own MDEL ⁴. Once the amendments take effect, foreign distributors who route all shipments through licensed Canadian MDEL importers can drop their foreign establishment licence, provided the Canadian importer updates their Section 45(f.1) supplier roster during their Annual Licence Review or via Form FRM-0292 ^{11 13}.

Worked examples: a CE-marked circumcision ring versus an NMPA-only laser fiber, and a Class I aftercare SKU that must not inherit a copied NMPA class

To demonstrate how these regulatory rules translate into commercial decisions, we examine three representative surgical-consumable files. The table is a filing-path contrast, not a classification certificate: the manufacturer applies Schedule 1, and this article does not assign a Canadian class to a named VEMERIX SKU ^{1 15 17}.

These case studies illustrate three vital regulatory principles ^{1 15 17}:

• Case 1 (Circumcision Device): Although the product-page file records a CE mark, that CE mark does not bypass s 26. Canadian class is determined under Schedule 1 by the manufacturer, not by copying EU IIa or an NMPA Class II label. Rule 1 classifies surgically invasive devices as Class II unless a higher subrule applies; Rule 2 is the body-orifice / eye-contact rule, not the EU 'transient use < 60 minutes' rule. If the manufacturer classifies the ring as Class II–IV, it needs its own MDL, an MDSAP certificate from a recognised auditing organisation, and a Canadian importer MDEL ^{1 15 17}.
• Case 2 (Endovenous Laser Fiber): The 1470 nm disposable laser fiber holds NMPA Class II registration in China and does not carry a Medison CE claim. NMPA is not a Canadian licence and NMPA Class II is not Canadian Class II. The manufacturer must classify under Schedule 1 independently. Devices intended to administer energy to the body are assessed under Rule 9; Rule 9(2) can place potentially hazardous energy delivery in Class III. This article does not assign that class to the SKU. If the Canadian class is II–IV, an MDL and MDSAP are required; the absence of a Medison CE mark is not itself a bar to filing ^{1 10 15 17}.
• Case 3 (Post-operative protection): Do not copy an NMPA Class I recordation into Canada. If the manufacturer classifies a non-invasive aftercare garment as Class I under Schedule 1, there is no MDL and the SKU will not appear on MDALL; the Canadian importer's MDEL and documented procedures are the placement instruments. If Schedule 1 places it in Class II–IV, an MDL is still required. That determination belongs to the manufacturer ^{2 4 15}.

Distributor checklist, agreement terms, and red flags before the first Canadian shipment

Before executing a distribution agreement or issuing a commercial purchase order for medical devices destined for Canada, international distributors and Canadian importers must execute a rigorous 7-stage compliance audit ^{1 4 10}:

1. Confirm Device Classification under Schedule 1: Do not rely on overseas classifications (EU IIa/IIb, US Class I/II, China Class II). Conduct an independent classification assessment under Schedule 1 of SOR/98-282 based on the intended use stated on the Canadian label ¹⁵.
2. Verify MDL Status on MDALL (Classes II–IV): For any Class II, III, or IV device, search MDALL to confirm that an active licence exists matching the exact legal manufacturer name, brand name, and device identifier ^{2 16}.
3. Inspect the Manufacturer's MDSAP Certificate: Review the legal manufacturer's MDSAP certificate to ensure it is issued by a Health Canada-recognised AO, covers the relevant manufacturing site, and remains in good standing ¹⁰.
4. Confirm Canadian Importer MDEL Readiness: Verify that the Canadian importing entity holds an active MDEL with authorized “import” activities covering the relevant device risk classes ^{3 4}.
5. Audit bilingual labelling under ss 21 and 23: Label information must be in English or French as a minimum. If directions for use are supplied in only one official language at sale, the other language must be made available as soon as possible at the purchaser's request. Devices sold to the general public must carry the s 21(1)(a) and (e) to (j) particulars in both English and French. Clinic-only supply is not automatically bilingual ¹.
6. Structure Private-Label Authorisation (If Applicable): If marketing under a private brand, confirm that the original manufacturer holds an active MDL, execute a formal Letter of Authorisation, and file a private-label MDL application ($179 fee) ^{6 9}.
7. Establish Post-Market Vigilance Protocols: Establish written SOPs between the manufacturer and Canadian importer covering mandatory problem reporting (s 59–61: 10 days for death/serious deterioration; 30 days for potential incidents), recall procedures (s 64–65), and 15-day change notifications (s 48) ^{1 13}.

Distributors should immediately halt commercial negotiations upon encountering any of the following six regulatory red flags ^{1 3 4}:

• Red Flag 1: Supplier Claims CE Mark or FDA 510(k) Covers Canada: Offering an overseas certificate as proof of Canadian market clearance indicates unfamiliarity with SOR/98-282 s 26 ¹.
• Red Flag 2: Supplier Claims Class II–IV Manufacturer Needs MDEL: Asserting that an overseas factory shipping its own devices requires an MDEL contradicts GUI-0016 Table 1 and signals reliance on AI summaries rather than statutory guidance ⁴.
• Red Flag 3: Supplier Provides an MDEL Screenshot as Product Approval: Providing an establishment licence listing screenshot to prove product clearance is invalid; Health Canada maintains no product list under an MDEL ³.
• Red Flag 4: Relying on Another Manufacturer's MDALL Licence Number: Attempting to import devices using another company's MDALL listing constitutes unlawful commercial supply under Section 26 ^{1 2}.
• Red Flag 5: Non-MDSAP ISO 13485 Certificate Offered for Class II–IV Filing: Standard ISO 13485 certificates without MDSAP companion statements cannot pass Health Canada MDL screening ¹⁰.
• Red Flag 6: Applying SOR/2026-110 Foreign Distributor Exemption Prematurely: Dropping foreign distributor establishment licensing prior to the official coming-into-force date (December 2026) creates immediate compliance liability under current GUI-0016 ^{4 11}.

Where VEMERIX fits — and where due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care. Our manufacturing infrastructure operates under rigorous quality management systems certified to ISO 13485:2016, with production facilities engineered to support international regulatory submissions, including MDSAP audit protocols and Health Canada technical file requirements.

In international market-access discussions, VEMERIX supports distributor partners and OEM buyers through transparent regulatory enablement ¹⁷:

• Comprehensive Technical Dossiers: We provide complete design dossiers, biocompatibility assessments (ISO 10993), sterilization validation records (ISO 11135 ethylene oxide), and risk management files (ISO 14971) to support Class II Canadian Medical Device Licence applications for our disposable circumcision devices and disposable medical laser fibers ¹⁷.
• Private-Label OEM Enablement: For qualified distributors and medical brand owners seeking to establish proprietary product lines in Canada, VEMERIX coordinates technical file cross-referencing and provides formal Letters of Authorisation to facilitate low-cost (CAD 179) private-label MDL filings under Health Canada's private-label policy ^{6 9}.
• Regulatory Boundaries & Due Diligence: VEMERIX does not sell pre-packaged Canadian licences or act as a domestic Canadian importer. Commercial partners are responsible for maintaining their own Canadian MDEL establishment licences and executing independent classification reviews. Regulatory due diligence begins by reviewing our primary quality certifications at VEMERIX Quality & Regulatory and contacting our international regulatory team at VEMERIX Contact.

Frequently Asked Questions

Do I still need a Canadian Medical Device Licence if my device already has a CE mark, FDA 510(k) or NMPA certificate?

Yes. Under Section 26 of the Medical Devices Regulations (SOR/98-282), no person may import or sell a Class II, III, or IV medical device in Canada unless the legal manufacturer holds an active Medical Device Licence (MDL) issued by Health Canada. European CE marks, US FDA 510(k) clearances, and China NMPA registrations serve as supporting technical evidence within your application dossier but do not provide legal authorization to clear Canadian customs or sell within Canada ¹.

Does the overseas manufacturer need an MDEL, or only the Canadian importer?

Under Health Canada Guidance GUI-0016 Table 1, an overseas manufacturer who sells only Class II, III, or IV devices bearing their own name on the label, and who does not sell Class I devices, requires an MDL and is explicitly exempt from holding an MDEL. The Canadian importer who physically imports the devices into Canada, however, must hold an active MDEL with authorized “import” activities covering the appropriate risk classes ^{4 5}.

If I manufacture a Class II device and import it myself, do I need both an MDL and an MDEL?

No. Under Section 44(2) of SOR/98-282 and GUI-0016 Table 1, a manufacturer who holds an MDL for a Class II, III, or IV device and sells or imports devices bearing their own name is exempt from holding an MDEL for those devices. An MDEL is only required if the manufacturer also imports or distributes medical devices manufactured by other corporate entities or handles Class I devices ^{4 5}.

Is MDSAP the same thing as a Medical Device Licence?

No. MDSAP is a quality management system auditing program, while an MDL is a pre-market marketing authorization for a specific medical device. Holding an active MDSAP certificate from a Health Canada-recognised auditing organisation is a mandatory filing condition under Section 32(2) for Class II, III, and IV MDL applications, but the MDSAP certificate alone does not authorise commercial sale without an issued MDL ^{1 10}.

How much are Health Canada MDL and MDEL fees as of 1 April 2026?

Official fees effective from 1 April 2026 to 31 March 2027 are: Class II MDL application CAD 643; Class II amendment CAD 331; Class III application CAD 14,163; Class IV application CAD 30,713; Private-Label MDL application/amendment CAD 179; MDEL application or annual review CAD 5,519; and annual Right-to-Sell renewal CAD 460 per active licence ^{6 7 8}.

Does another company's MDALL row cover my shipment of the same model?

No. A Medical Device Licence is legally unique to the specific manufacturer named on the licence. Even if another brand or distributor holds an active MDL on MDALL for an identical or equivalent product manufactured in the same factory, you cannot import goods under their licence number. You must either obtain your own MDL or establish a private-label MDL ($179) supported by a Letter of Authorisation ^{1 9}.

When can a foreign distributor drop their own MDEL under SOR/2026-110, and does that exempt the Canadian importer?

Foreign distributors who sell into Canada solely through a licensed Canadian MDEL importer may drop their own foreign MDEL once SOR/2026-110 comes into force (December 2026). However, this amendment does NOT exempt the Canadian importer; the domestic Canadian importer must maintain an active MDEL and list the foreign distributor on their Section 45(f.1) supplier roster ^{11 12}.

Does VEMERIX already hold an MDL or MDEL for these SKUs?

VEMERIX provides comprehensive technical files, ISO 13485 quality systems, and MDSAP audit readiness to support distributor-led or private-label Class II MDL applications. We do not sell pre-packaged Canadian licences. Commercial partners are invited to contact our regulatory affairs team at VEMERIX Contact to review technical dossiers, MDSAP certification scope, and private-label Letter of Authorisation procedures ¹⁷.